PL348163A1 - Inhibition of the formation of vascular hyperpermeability - Google Patents
Inhibition of the formation of vascular hyperpermeabilityInfo
- Publication number
- PL348163A1 PL348163A1 PL99348163A PL34816399A PL348163A1 PL 348163 A1 PL348163 A1 PL 348163A1 PL 99348163 A PL99348163 A PL 99348163A PL 34816399 A PL34816399 A PL 34816399A PL 348163 A1 PL348163 A1 PL 348163A1
- Authority
- PL
- Poland
- Prior art keywords
- tyrosine kinase
- vascular hyperpermeability
- events
- formation
- vascular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
Abstract
Vascular hyperpermeability in individuals is a prelude to a number of physiological events that are often deleterious. Among these events is the formation of edema, diapedesis, aberrant trans-endothelial exchange, extravasation, exudation and effusion, matrix deposition (often with abnormal stromal proliferation) and vascular hypotension. Vascular hyperpermeability and the subsequent events can be inhibited by the administration of a compound that inhibits the enzyme activity of the VEGF tyrosine kinase receptor known as KDR tyrosine kinase. Preferred administered compounds selectively inhibit the function of KDR tyrosine kinase but do not block the activity of Flt-1 tyrosine kinase which is another VEGF tyrosine kinase receptor.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10746298P | 1998-11-06 | 1998-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL348163A1 true PL348163A1 (en) | 2002-05-06 |
Family
ID=22316735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL99348163A PL348163A1 (en) | 1998-11-06 | 1999-11-03 | Inhibition of the formation of vascular hyperpermeability |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1126842A2 (en) |
JP (1) | JP2002529421A (en) |
KR (1) | KR20010080952A (en) |
CN (1) | CN1342077A (en) |
AR (1) | AR023912A1 (en) |
AU (1) | AU1908000A (en) |
BG (1) | BG105476A (en) |
BR (1) | BR9915139A (en) |
CA (1) | CA2347916A1 (en) |
CO (1) | CO5150183A1 (en) |
CZ (1) | CZ20011564A3 (en) |
HU (1) | HUP0104302A3 (en) |
ID (1) | ID29063A (en) |
IL (1) | IL142583A0 (en) |
NO (1) | NO20012218L (en) |
PL (1) | PL348163A1 (en) |
SK (1) | SK5052001A3 (en) |
TR (1) | TR200102278T2 (en) |
WO (1) | WO2000027414A2 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1140173T4 (en) | 1998-12-22 | 2013-06-10 | Genentech Inc | Vascular endothelial cell growth factor antagonists and applications thereof |
EP2298311B1 (en) | 1999-01-13 | 2012-05-09 | Bayer HealthCare LLC | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
DK1250155T3 (en) * | 1999-12-22 | 2008-08-25 | Scripps Research Inst | Modulators and inhibitors of angiogenesis and vascular permeability |
DE10021246A1 (en) * | 2000-04-25 | 2001-10-31 | Schering Ag | New N-substituted benzamide derivatives are tyrosine kinase KDR and FLT inhibitors useful e.g. for treating tumors, psoriasis, rheumatoid arthritis, diabetic retinopathy or liver sclerosis |
WO2003018057A1 (en) * | 2001-07-26 | 2003-03-06 | Santen Pharmaceutical Co., Ltd. | Remedy for glaucoma comprising as the active ingredient compound having pi3 kinase inhibitory effect |
MXPA04007832A (en) | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aryl ureas with angiogenesis inhibiting activity. |
US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
EP1587944A4 (en) | 2002-03-01 | 2007-03-21 | Dyax Corp | Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
JP2006507841A (en) * | 2002-11-14 | 2006-03-09 | ダーマコン, インコーポレイテッド | Functional and ultrafunctional siRNA |
WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
SI2949658T1 (en) | 2003-03-03 | 2018-10-30 | Dyax Corp. | Peptides that specifically bind HGF receptor (cMet) and uses thereof |
CA2526617C (en) | 2003-05-20 | 2015-04-28 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
UA84156C2 (en) | 2003-07-23 | 2008-09-25 | Байер Фармасьютикалс Корпорейшн | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
KR20150072458A (en) * | 2006-11-15 | 2015-06-29 | 코다 테라퓨틱스, 인크. | Improved methods and compositions for wound healing |
JP2013539456A (en) | 2010-07-28 | 2013-10-24 | アルコン リサーチ,リミテッド | SiRNA Targeting VEGFA and Methods for In Vivo Treatment |
KR101565886B1 (en) | 2013-10-23 | 2015-11-05 | 전남대학교산학협력단 | Method and Kit for Diagnosting of Ovarian Hyperstimulation Syndrome |
EA201790434A1 (en) | 2014-08-22 | 2017-07-31 | Окленд Юнисервисиз Лимитед | CHANNEL MODULATORS |
CN106381330A (en) * | 2016-08-30 | 2017-02-08 | 张建华 | Primer and kit for detecting susceptibility of communicating hydrocephalus |
AU2019237774B2 (en) * | 2018-03-19 | 2023-03-23 | Pharmabcine Inc | Anti-VEGFR-2 antibody |
CN109718253B (en) * | 2019-01-16 | 2021-09-24 | 中国人民解放军总医院 | Use of bacteria capable of metabolizing to produce histamine for preventing or treating altitude sickness |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE789948A (en) * | 1971-10-13 | 1973-04-11 | Sandoz Sa | NEW DERIVATIVES OF PYRAZOLE, THEIR PREPARATION AND THEIR APPLICATION AS MEDICINAL PRODUCTS |
US3843664A (en) * | 1973-02-20 | 1974-10-22 | Sandoz Ag | Substituted naphtho pyrazoles |
US3843665A (en) * | 1973-04-11 | 1974-10-22 | Sandoz Ag | Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles |
US3843666A (en) * | 1973-05-29 | 1974-10-22 | Sandoz Ag | Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles |
US5712395A (en) * | 1992-11-13 | 1998-01-27 | Yissum Research Development Corp. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
WO1998033917A1 (en) * | 1994-11-14 | 1998-08-06 | The Ludwig Institute For Cancer Research | Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof |
US6346398B1 (en) * | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
FR2742662B1 (en) * | 1995-12-21 | 1998-01-23 | Centre Nat Rech Scient | ANTI-IDIOTYPIC ANTIBODIES OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND THEIR USE AS MEDICAMENTS |
US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
DE19638745C2 (en) * | 1996-09-11 | 2001-05-10 | Schering Ag | Monoclonal antibodies against the extracellular domain of the human VEGF receptor protein (KDR) |
WO1998058053A1 (en) * | 1997-06-18 | 1998-12-23 | Merck & Co., Inc. | Human receptor tyrosine kinase, kdr |
ES2206997T3 (en) * | 1997-10-06 | 2004-05-16 | ABBOTT GMBH & CO. KG | DERIVATIVES OF INDENO (1,2-C) -, OF NAFTO (1,2-C), AND OF BENZO (6,7) CICLOEPTA (1,2-C) PIRAZOL. |
CN1278724A (en) * | 1997-10-06 | 2001-01-03 | 巴斯福股份公司 | Indeno [1,2-c] pyrazole derivatives for inhibiting tyrosine kinase activty |
WO1999055335A1 (en) * | 1998-04-30 | 1999-11-04 | Basf Aktiengesellschaft | Substituted tricyclic pyrazole derivatives with protein kinase activity |
-
1999
- 1999-11-03 AU AU19080/00A patent/AU1908000A/en not_active Abandoned
- 1999-11-03 PL PL99348163A patent/PL348163A1/en unknown
- 1999-11-03 WO PCT/US1999/025903 patent/WO2000027414A2/en not_active Application Discontinuation
- 1999-11-03 HU HU0104302A patent/HUP0104302A3/en unknown
- 1999-11-03 IL IL14258399A patent/IL142583A0/en unknown
- 1999-11-03 JP JP2000580643A patent/JP2002529421A/en active Pending
- 1999-11-03 SK SK505-2001A patent/SK5052001A3/en unknown
- 1999-11-03 CN CN99812924A patent/CN1342077A/en active Pending
- 1999-11-03 TR TR2001/02278T patent/TR200102278T2/en unknown
- 1999-11-03 EP EP99962685A patent/EP1126842A2/en not_active Withdrawn
- 1999-11-03 CA CA002347916A patent/CA2347916A1/en not_active Abandoned
- 1999-11-03 ID IDW00200101000A patent/ID29063A/en unknown
- 1999-11-03 CZ CZ20011564A patent/CZ20011564A3/en unknown
- 1999-11-03 KR KR1020017005724A patent/KR20010080952A/en not_active Application Discontinuation
- 1999-11-03 BR BR9915139-1A patent/BR9915139A/en not_active IP Right Cessation
- 1999-11-05 AR ARP990105608A patent/AR023912A1/en unknown
- 1999-11-08 CO CO99070343A patent/CO5150183A1/en unknown
-
2001
- 2001-04-25 BG BG105476A patent/BG105476A/en unknown
- 2001-05-04 NO NO20012218A patent/NO20012218L/en unknown
Also Published As
Publication number | Publication date |
---|---|
ID29063A (en) | 2001-07-26 |
HUP0104302A2 (en) | 2002-03-28 |
AR023912A1 (en) | 2002-09-04 |
HUP0104302A3 (en) | 2002-11-28 |
EP1126842A2 (en) | 2001-08-29 |
SK5052001A3 (en) | 2002-10-08 |
AU1908000A (en) | 2000-05-29 |
KR20010080952A (en) | 2001-08-25 |
CA2347916A1 (en) | 2000-05-18 |
CO5150183A1 (en) | 2002-04-29 |
NO20012218L (en) | 2001-06-18 |
CN1342077A (en) | 2002-03-27 |
BG105476A (en) | 2002-02-28 |
WO2000027414A2 (en) | 2000-05-18 |
CZ20011564A3 (en) | 2002-04-17 |
IL142583A0 (en) | 2002-03-10 |
NO20012218D0 (en) | 2001-05-04 |
BR9915139A (en) | 2001-08-07 |
JP2002529421A (en) | 2002-09-10 |
WO2000027414A3 (en) | 2000-09-08 |
TR200102278T2 (en) | 2001-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL348163A1 (en) | Inhibition of the formation of vascular hyperpermeability | |
Brunner | Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease | |
Kurtz et al. | Role of nitric oxide in the control of renin secretion | |
Hirsch et al. | Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure | |
EA200100579A1 (en) | QUINOLINE AND QUINOXALINE COMPOUNDS AS A PDGF RECEPTOR AND / OR TYROSINKINASE LCK INHIBITORS | |
Chen et al. | Heterogeneity in vascular smooth muscle responsiveness to angiotensin II: role of endothelin | |
Kwok et al. | Enhancement of sensitivity of human squamous carcinoma cells to radiation by epidermal growth factor | |
MY128370A (en) | Pyrrolotriazane inhibitors of kinases | |
AU2735201A (en) | Pyrimidine and triazine kinase inhibitors | |
MA27154A1 (en) | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | |
Dogterom et al. | Cardiotoxicity of vasodilators and positive inotropic/vasodilating drugs in dogs: an overview | |
Meyer et al. | Pharmacological heart rate lowering in patients with a preserved ejection fraction—review of a failing concept | |
Weinstock | The presynaptic effect of β-adrenoceptor antagonists on noradrenergic neurones | |
Cox et al. | Prejunctional angiotensin receptors involved in the facilitation of noradrenaline release in mouse tissues | |
Chalmers et al. | Hypertension in the elderly: the role of calcium antagonists | |
Dustan | Calcium channel blockers. Potential medical benefits and side effects. | |
SI1622881T1 (en) | Quinazolinone-derivatives and their use for preparation of pharmaceutical compositions having parp enzyme inhibitory effect | |
Igarashi et al. | Role of angiotensin II type-1 and type-2 receptors on vascular smooth muscle cell growth and glucose metabolism in diabetic rats | |
Nagao et al. | Development of diltiazem, a calcium antagonist: coronary vasodilating and antihypertensive actions | |
RS20050930A (en) | Substituted spirobenzazepines | |
Peterson et al. | Angiotensin II receptor blockers in the treatment of heart failure | |
Porteri et al. | Structural changes of small resistance arteries in spontaneously hypertensive rats after treatment with various doses of lacidipine | |
Kopera et al. | Phenprocoumon requirement, whole blood coagulation time, bleeding time and plasma γ-GT in patients receiving mianserin | |
Matsui et al. | Highly potent inhibitors of TNF-α production. Part 2: identification of drug candidates | |
Jaillon | Antiarrhythmic drug interactions: are they important? |